India’s top-ranked drug firm, Sun Pharmaceutical Industries Ltd., hopes to build on the early promise in Japan for psoriasis drug Ilumya (tildrakizumab), which also saw sales rebound to pre-COVID-19 levels in the second quarter of fiscal 2021 in the US, its key market.
Sun Has ‘Great Expectations’ For Ilumya In Japan
Smaller But Growing Psoriasis Market
Sun is hoping to build on early momentum for its psoriasis therapy Ilumya in Japan, leveraging the dermatology expertise of acquired local company Pola. The IL-23p19 inhibitor is also among the Indian firm's specialty products that saw US sales claw back to pre-COVID levels in Q2.
